This study will investigate the use of a new medicine called AMT-151 which may be used in the future as a possible treatment for advanced solid tumours.

Trial Status
Active, not recruiting
Trial Phase
Phase 1 Drug Trial
Registry Listing
ERM Project ID
Trial contact details
Contact Person
Caitlin Bennett
What you need to know

Who can take part?

Patients with advanced solid tumour and standard therapy has either been exhausted or is not available.

What is involved for you?

You will receive the study drug once every 3 weeks through intravenous (IV) infusion, which will take approximately one hour. You will be required to attend the clinic at least every  week during treatment for a physical assessment, blood tests, ECGs and ongoing assessments. You will also receive ongoing tumour assessments via scans.

All research clinical trials news

Jan Mundt had just celebrated the birth of her first grandchild when she received a devastating cancer diagnosis. Despite having never smoked, Mrs Mundt was told a pain in her chest was being...



Clinical trials help gran defy terminal lung cancer diagnosis

A new diagnostic and treatment approach for bladder cancer will undergo a clinical trial in Queensland.



Technology shines a light on better bladder cancer detection

2023 was an outstanding year for Mater Research with $13.7 million in grant funding received and 424 publications recorded.



Highlighting Mater Research’s year of achievements: 2023 Annual Report

Displaying results 1-3 (of 20)
 |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7  >  >|